About
About Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor drugs, gynecological medications, medication for rheumatic bone pain, urological medications, heat-clearing and detoxifying drugs, cardiovascular and cerebrovascular drugs, digestive medications, tonifying and restorative medicines, respiratory medication, diabetes medication, ENT medication, and pediatric medications. It also offers Xiaojin pills, Tian Ranshexiang Xiaojin pills, Xiaokechuan capsules, Jiuwei Qianghuo granules, Xiongdan powder, Bear Bile powder, and Wenweishu tablets to treat glandular hyperplasia, inflammatory diseases, bone trauma and soft tissue injury, and other related diseases. In addition, the company provides bacillus cereus live bacteria capsules, bacillus cereus live bacteria tablets are therapeutic live bacteria microecological preparations to treat enteritis, diarrhea, infantile diarrhea, and intestinal dysfunction. The company was founded in 1990 and is headquartered in Tonghua, China.
Visit company website
5 years, 4 months ago
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd is currently in a long term uptrend where the price is trading 19.1% above its 200 day moving average.
From a valuation standpoint, the stock is 72.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's total revenue sank by 33.9% to $322M since the same quarter in the previous year.
Its net income has dropped by 312.2% to $-85M since the same quarter in the previous year.
Finally, its free cash flow fell by 13.1% to $7M since the same quarter in the previous year.
Based on the above factors, Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd gets an overall score of 2/5.